After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that Allogene Therapeutics Announces Participation in Upcoming Investor Conferences.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $3.13 and fluctuated between $3.1600 as its day high and $3.0111 as its day low. The current market capitalization of Allogene Therapeutics Inc is $526.72M. A total of 2.29 million shares were traded on the day, compared to an average of 2.81M shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, ALLO has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 17 BUYs and 7 SELLs from insiders. Insiders purchased 6,486,902 shares during that period but sold 106,198.
In the most recent transaction, MESSEMER DEBORAH M. sold 18,640 shares of ALLO for 2.70 per share on Dec 18. After the transaction, the Director now owns 62,456 company shares. In a previous transaction on Aug 07, Mayo Stephen sold 10,000 shares at 4.29 per share. ALLO shares that Director owns now total 25,328.
Among the insiders who sold shares, Bhavnagri Veer disposed of 3,000 shares on Feb 13 at a per-share price of $6.85. This resulted in the General Counsel holding 577,677 shares of ALLO after the transaction. In another insider transaction, Bhavnagri Veer sold 3,000 shares at $7.04 per share on Jan 17. Company shares held by the General Counsel now total 580,677.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for ALLO in the last 3 months, the mean price target is $11.92 with high estimates of $35.00 and low estimates of $4.50. In terms of 52-week highs and lows, ALLO has a high of $8.44 and a low of $2.23.
As of this writing, ALLO has an earnings estimate of -$0.45 per share for the current quarter. EPS was calculated based on a consensus of 17 estimates, with a high estimate of -$0.34 per share and a lower estimate of -$0.62. The company reported an EPS of -$0.53 in the last quarter, which was 10.20% higher than expectations of -$0.59.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ALLO’s latest balance sheet shows that the firm has $457.30M in Cash & Short Term Investments as of fiscal 2021. There were $73.13M in debt and $48.17M in liabilities at the time. Its Book Value Per Share was $3.47, while its Total Shareholder’s Equity was $916.41M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ALLO is Buy with a score of 4.26.
